# Alphatec Holdings, Inc.: overview

ATEC · Nasdaq · CIK 1350653 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atec.md) · [Financials](/companies/atec/financials.md) · [Filings](/companies/atec/filings.md) · [Insiders](/companies/atec/insiders.md)

Latest reported revenue: [$213.5m](/filings/0001193125-26-333051.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-333051).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [151](/filings/0001193125-25-258790.md) | [177 d](/filings/0001193125-26-067393.md) | [169](/filings/0001193125-26-206683.md) | [186](/filings/0001193125-26-333051.md) | [197](/filings/0001193125-25-258790.md) | [213 d](/filings/0001193125-26-067393.md) | [192](/filings/0001193125-26-206683.md) | [214](/filings/0001193125-26-333051.md) |
| Gross margin | % | [68.2%](/filings/0001193125-25-258790.md) | [68.8% d](/filings/0001193125-26-067393.md) | [68.6%](/filings/0001193125-26-206683.md) | [69.6%](/filings/0001193125-26-333051.md) | [69.9%](/filings/0001193125-25-258790.md) | [70.2% d](/filings/0001193125-26-067393.md) | [71.0%](/filings/0001193125-26-206683.md) | [72.2%](/filings/0001193125-26-333051.md) |
| Operating margin | % | [(22.4%)](/filings/0001193125-25-258790.md) | [(13.5%) d](/filings/0001193125-26-067393.md) | [(26.2%)](/filings/0001193125-26-206683.md) | [(7.1%)](/filings/0001193125-26-333051.md) | [(8.1%)](/filings/0001193125-25-258790.md) | [(4.1%) d](/filings/0001193125-26-067393.md) | [(11.8%)](/filings/0001193125-26-206683.md) | [(0.9%)](/filings/0001193125-26-333051.md) |
| Net margin | % | [(26.3%)](/filings/0001193125-25-258790.md) | [(18.9%) d](/filings/0001193125-26-067393.md) | [(30.7%)](/filings/0001193125-26-333051.md) | [(22.2%)](/filings/0001193125-26-333051.md) | [(14.5%)](/filings/0001193125-25-258790.md) | [(10.2%) d](/filings/0001193125-26-067393.md) | [(17.6%)](/filings/0001193125-26-333051.md) | [(12.1%)](/filings/0001193125-26-333051.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0001193125-25-258790.md) | not reported | [(0.35)](/filings/0001193125-26-206683.md) | [(0.27)](/filings/0001193125-26-333051.md) | [(0.19)](/filings/0001193125-25-258790.md) | not reported | [(0.22)](/filings/0001193125-26-206683.md) | [(0.16)](/filings/0001193125-26-333051.md) |
| Free cash flow | $m | [(21.2) d](/filings/0001193125-25-258790.md) | [8.5 d](/filings/0001193125-26-067393.md) | [(15.0)](/filings/0001193125-26-206683.md) | [5.2 d](/filings/0001193125-26-333051.md) | [4.8 d](/filings/0001193125-25-258790.md) | [7.7 d](/filings/0001193125-26-067393.md) | [(10.8)](/filings/0001193125-26-206683.md) | [0.6 d](/filings/0001193125-26-333051.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [243](/filings/0000950170-24-021302.md) | [351](/filings/0000950170-25-027916.md) | [482](/filings/0001193125-26-067393.md) | [612](/filings/0001193125-26-067393.md) | [764](/filings/0001193125-26-067393.md) |
| Gross margin | % | [64.9%](/filings/0000950170-24-021302.md) | [66.4%](/filings/0000950170-25-027916.md) | [64.3%](/filings/0001193125-26-067393.md) | [69.4%](/filings/0001193125-26-067393.md) | [69.6%](/filings/0001193125-26-067393.md) |
| Operating margin | % | [(52.7%)](/filings/0000950170-24-021302.md) | [(41.9%)](/filings/0000950170-25-027916.md) | [(36.0%)](/filings/0001193125-26-067393.md) | [(22.3%)](/filings/0001193125-26-067393.md) | [(10.7%)](/filings/0001193125-26-067393.md) |
| Net margin | % | [(58.8%)](/filings/0000950170-24-021302.md) | [(43.1%)](/filings/0000950170-25-027916.md) | [(38.7%)](/filings/0001193125-26-067393.md) | [(26.5%)](/filings/0001193125-26-067393.md) | [(18.8%)](/filings/0001193125-26-067393.md) |
| Diluted EPS | $ per share | [(1.49)](/filings/0000950170-24-021302.md) | [(1.46)](/filings/0000950170-25-027916.md) | [(1.54)](/filings/0001193125-26-067393.md) | [(1.13)](/filings/0001193125-26-067393.md) | [(0.96)](/filings/0001193125-26-067393.md) |
| Free cash flow | $m | [(142)](/filings/0000950170-24-021302.md) | [(125)](/filings/0000950170-25-027916.md) | [(159)](/filings/0001193125-26-067393.md) | [(128)](/filings/0001193125-26-067393.md) | [2.8](/filings/0001193125-26-067393.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/atec/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $98.0m | 11,326,677 |  | Added +1,238,495 |
| [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $56.5m | 6,531,439 |  | Added +4,358,714 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $56.4m | 6,521,659 |  | Added +96,882 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $45.1m | 5,211,600 | Call | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $44.3m | 5,122,681 |  | Added +208,902 |
| [BNP PARIBAS ASSET MANAGEMENT Holding S.A.](/funds/1520354.md) | 2026-06-30 | $30.6m | 3,536,538 |  | Reduced −79,792 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $30.1m | 3,481,349 |  | Added +450,185 |
| [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $29.0m | 3,352,133 |  | New +3,352,133 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $27.6m | 3,188,894 |  | Added +282,472 |
| [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $25.9m | 2,995,410 |  | Reduced −1,521,182 |

## Recent filings

[All 1,411 filings](/companies/atec/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:21 ET | [8-K](/filings/0001193125-26-437830.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-437830 |
| 2026-08-04 | 16:57 ET | [10-Q](/filings/0001193125-26-333051.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333051 |
| 2026-08-04 | 16:19 ET | [8-K](/filings/0001193125-26-332870.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332870 |
| 2026-06-11 | 16:13 ET | [8-K](/filings/0001193125-26-267552.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-267552 |
| 2026-05-05 | 16:56 ET | [10-Q](/filings/0001193125-26-206683.md) | Quarterly report, period 2026-03-31 | 0001193125-26-206683 |
| 2026-05-05 | 16:28 ET | [8-K](/filings/0001193125-26-206530.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-206530 |
| 2026-04-29 | 16:26 ET | [DEF 14A](/filings/0001193125-26-191867.md) | Proxy statement, period 2026-06-10 | 0001193125-26-191867 |
| 2026-03-03 | 16:14 ET | [8-K](/filings/0001193125-26-088220.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-088220 |
| 2026-02-24 | 16:58 ET | [10-K](/filings/0001193125-26-067393.md) | Annual report, period 2025-12-31 | 0001193125-26-067393 |
| 2026-02-24 | 16:19 ET | [8-K](/filings/0001193125-26-067062.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-067062 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-067393.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/868a6568-230e-40a1-865e-fef255e8f790)

## About the filer

- CIK: 1350653
- Tickers: ATEC
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:13 ET. No prices; not investment advice.